How advances in research, early diagnosis and personalised treatment are moving from London laboratories towards the NHS
London at the centre of a changing cancer landscape
Cancer research in Britain is entering a period in which the distance between the laboratory and the hospital is becoming increasingly important.
From personalised vaccines and immunotherapy to artificial intelligence, blood-based detection and molecular testing, researchers are exploring ways to identify cancer earlier and match treatment more closely to the biology of an individual tumour.
London sits at the centre of much of this activity.
The capital brings together major universities, NHS trusts, specialist cancer centres, pharmaceutical companies and emerging life-sciences businesses. In June, NHS England London launched a new Life Sciences Strategy aimed at making it easier for promising medical innovations to be tested, evaluated and adopted across the capital. London has more than 2,700 life-sciences companies and a health system serving almost 10 million people.
The ambition comes as England implements a new National Cancer Plan, which aims for three in four people diagnosed with cancer in 2035 to be cancer-free or living well five years later. The plan places particular emphasis on earlier diagnosis, technology and research.
But scientific promise and routine treatment remain two very different things.
Personalised vaccines move into clinical testing
One of the most closely watched developments is the emergence of personalised cancer vaccines.
In August, University College London Hospitals reported positive early results from an international Phase 3 trial of a personalised mRNA treatment for patients with high-risk melanoma following surgery.
The treatment is designed around mutations found in an individual patient’s tumour and is being investigated alongside pembrolizumab, an established immunotherapy. The UK arm of the trial was led by UCLH in London.
Another London-linked programme is taking the idea in a different direction.
The LungVax project, involving UCL, the University of Oxford and the Francis Crick Institute, is investigating whether a vaccine could train the immune system to recognise abnormal cells before they develop into established lung cancer.
In November 2025, researchers announced the launch of the world’s first clinical trial of an experimental lung-cancer vaccine for people at high risk of the disease. The Phase I study is designed initially to examine appropriate doses and potential side effects rather than establish whether the vaccine prevents cancer.
That distinction matters. These are experimental approaches, and patients will need evidence from successive stages of clinical trials before any new vaccine can become part of routine NHS care.
Earlier diagnosis is becoming another battleground
Treatment is only one side of the story.
Researchers in London are also looking at how cancer can be detected earlier, when treatment may be more effective.
In June, UCLH researchers reported findings from a study involving more than 48,000 UK Biobank participants. Using machine learning, the team identified 14 proteins in blood that, together with factors such as age and smoking history, could help predict future lung cancer risk. The work involved UCL, UCLH, the Francis Crick Institute and Cancer Research UK.
Artificial intelligence is also being tested directly within NHS diagnostic pathways.
But the results have not always supported the most optimistic expectations. A large trial led by UCLH, UCL and the University of Nottingham found that using AI to prioritise abnormal chest X-rays did not ultimately reduce the time to a lung-cancer diagnosis, despite reducing the time taken for radiologists to report the scans.
The lesson is significant: sophisticated technology still has to demonstrate a measurable benefit within the real-world healthcare system.
London’s research ecosystem
The capital’s strength lies partly in the concentration of institutions working across the full research pathway.
The Institute of Cancer Research and The Royal Marsden operate a major programme of early-phase cancer trials, including studies designed to match treatments to the molecular characteristics of individual tumours. The London Cancer Hub in Sutton is also developing a life-sciences ecosystem where research groups and companies can work alongside specialist cancer expertise.
Elsewhere, the Francis Crick Institute and UCL are involved in research spanning cancer biology, immunology, early detection and treatment development. Cancer Research UK’s London research infrastructure includes specialist centres covering areas such as novel biological therapies, cancer evolution, early detection and prevention.
This creates an increasingly interconnected environment in which discoveries can move from laboratory research into clinical trials and, where evidence supports them, eventually towards NHS adoption.
Where private research fits in
Private-sector organisations are also seeking a role in this changing landscape.
Gorgio International Holding and its Quatech operation have publicly described work involving biotechnology, pharmaceutical development, anti-cancer formulations and research into potential new therapies. The organisation’s public material also describes collaborations with scientists and researchers and lists areas including cancer biology and clinical research. These are descriptions of the organisation’s stated activities; they do not, by themselves, establish that a particular product or treatment has demonstrated clinical effectiveness.
That distinction is increasingly important as commercial investment enters areas once dominated almost entirely by universities and publicly funded research.
For any prospective cancer treatment, the same questions ultimately apply: has it been tested properly, are the results reproducible, is it safe, and does it improve outcomes compared with existing care?
From London’s laboratories to the NHS
The new generation of cancer research is therefore not simply about discovering another drug or diagnostic machine.
It is about creating a pathway from scientific discovery to something that can work reliably for patients.
London’s new health-innovation strategy explicitly recognises that challenge, with plans for greater coordination between the NHS, universities, industry and researchers, including new mechanisms for testing innovative technologies alongside clinicians.
For Britain, the significance extends far beyond the capital.
If personalised vaccines, earlier detection, molecular diagnostics and AI-supported care prove effective, the eventual test will not be how impressive they look inside a laboratory. It will be whether they can be validated, manufactured, regulated and delivered consistently through the NHS.
The next chapter of cancer treatment may be written in London’s laboratories. But its success will ultimately be measured in consulting rooms, hospitals and in the lives of patients across Britain.
